{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:47:22Z","timestamp":1785448042542,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001827","name":"University of Amsterdam","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001827","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.rmed.2018.06.025","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T15:33:31Z","timestamp":1530200011000},"page":"81-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Diagnosing persistent blood eosinophilia in asthma with single blood eosinophil or exhaled nitric oxide level"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-6823","authenticated-orcid":false,"given":"Hanneke","family":"Coumou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guus A.","family":"Westerhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma B.","family":"de Nijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Amelink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth H.","family":"Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmed.2018.06.025_bib1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2018.06.025_bib2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaci.2006.11.639","article-title":"Characterization of the severe asthma phenotype by the national heart, lung, and blood Institute's severe asthma research program","volume":"119","author":"Moore","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.025_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2003.10.041","article-title":"Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation","volume":"113","author":"Miranda","year":"2004","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.025_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/ajrccm.160.3.9812110","article-title":"Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics","volume":"160","author":"Wenzel","year":"1999","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.06.025_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/all.12136","article-title":"Three phenotypes of adult-onset asthma","volume":"68","author":"Amelink","year":"2013","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2018.06.025_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1183\/09031936.00120810","article-title":"Identifying adult asthma phenotypes using a clustering approach","volume":"38","author":"Siroux","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"9842","key":"10.1016\/j.rmed.2018.06.025_bib7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.rmed.2018.06.025_bib8","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.rmed.2018.06.025_bib9","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00100-2015","article-title":"Clinical profile of patients with adult-onset eosinophilic asthma","volume":"2","author":"de Groot","year":"2016","journal-title":"ERJ Open Res"},{"issue":"10","key":"10.1016\/j.rmed.2018.06.025_bib10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"10056","key":"10.1016\/j.rmed.2018.06.025_bib11","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.rmed.2018.06.025_bib12","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rmed.2018.06.025_bib13","series-title":"Global Initiative for Asthma (GINA)","author":"From the Global Strategy for Asthma Management and Prevention","year":"2015"},{"issue":"5","key":"10.1016\/j.rmed.2018.06.025_bib14","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2018.06.025_bib15","article-title":"Clinical predictors of remission and persistence of adult-onset asthma","author":"Westerhof","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2018.06.025_bib16","first-page":"3s","article-title":"Sputum induction","volume":"37","author":"Paggiaro","year":"2002","journal-title":"Eur. Respir. J. Suppl."},{"issue":"11","key":"10.1016\/j.rmed.2018.06.025_bib17","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"The Lancet Respiratory Medicine"},{"issue":"6","key":"10.1016\/j.rmed.2018.06.025_bib18","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1164\/rccm.201109-1640OC","article-title":"A large subgroup of mild-to-moderate asthma is persistently noneosinophilic","volume":"185","author":"McGrath","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.rmed.2018.06.025_bib19","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.rmed.2018.06.025_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1183\/09031936.00012415","article-title":"Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes","volume":"46","author":"Westerhof","year":"2015","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.025_bib21","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jaci.2014.09.034","article-title":"High blood eosinophil counts predict sputum eosinophilia in patients with severe asthma","volume":"135","author":"Fowler","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2018.06.025_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1513\/AnnalsATS.201310-354OC","article-title":"Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma","volume":"11","author":"Katz","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.rmed.2018.06.025_bib23","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3109\/02770903.2012.713428","article-title":"Is a single blood eosinophil count a reliable marker for \"eosinophilic asthma?\"","volume":"49","author":"Spector","year":"2012","journal-title":"J. Asthma"},{"issue":"2","key":"10.1016\/j.rmed.2018.06.025_bib24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/thx.53.2.91","article-title":"Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma","volume":"53","author":"Jatakanon","year":"1998","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.rmed.2018.06.025_bib25","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jaci.2005.09.029","article-title":"Exhaled nitric oxide identifies the persistent eosinophilic phenotype in severe refractory asthma","volume":"116","author":"Silkoff","year":"2005","journal-title":"J. Allergy Clin. Immunol."},{"issue":"9","key":"10.1016\/j.rmed.2018.06.025_bib26","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1365-2222.2005.02314.x","article-title":"The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma","volume":"35","author":"Berry","year":"2005","journal-title":"Clin. Exp. Allergy"},{"issue":"5","key":"10.1016\/j.rmed.2018.06.025_bib27","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.chest.2015.11.020","article-title":"Update on exhaled nitric oxide in clinical practice","volume":"149","author":"Mummadi","year":"2016","journal-title":"Chest"},{"issue":"10039","key":"10.1016\/j.rmed.2018.06.025_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta(2) agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rmed.2018.06.025_bib29","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur. Respir. J."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:41:52Z","timestamp":1760614912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611118302233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":29,"alternative-id":["S0954611118302233"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.06.025","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosing persistent blood eosinophilia in asthma with single blood eosinophil or exhaled nitric oxide level","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.06.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}